Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study-Reference-Cited by-同舟云学术

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Published:2021-03-07 Issue:2 Volume:9 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Zhang Hong¹,Wu Min¹,Sun Jixuan¹,Zhu Xiaoxue¹,Li Cuiyun¹,Ding Yanhua¹,Zhang Xiaodi²,Chai Katherine²,Li Xiaojiao¹

Affiliation:

1. Phase 1 Clinical Research Center the First Hospital of Jilin University Changchun China

2. Shanghai Henlius Biotech, Inc. Shanghai China

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.733

Reference29 articles.

1. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

2. TNF biology, pathogenic mechanisms and emerging therapeutic strategies

3. Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

4. Review of biosimilars of adalimumab;Kaushik VV;J Assoc Physicians India,2017

5. AbbVie Inc Humira®Prescribing Information 2020.https://www.rxabbvie.com/pdf/humira.pdf. Accessed 19 August 2020.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™;Frontiers in Cardiovascular Medicine;2023-07-18

2. Biosimilar monoclonal antibodies in China: A patent review;Bioengineered;2022-06-01